News & Events
News & Events
Institut Pasteur Korea Hosted Global Infectious Disease Symposium on Vaccine and Therapeutics Development
2025-09-24
Institut Pasteur Korea Hosted Global Infectious Disease Symposium on Vaccine and Therapeutics Development
– Accelerating Therapeutics and Vaccine Innovation for Unmet Medical Needs –
– Collaboration with the Peter Doherty Institute and Pasteur Network –
– Accelerating Therapeutics and Vaccine Innovation for Unmet Medical Needs –
– Collaboration with the Peter Doherty Institute and Pasteur Network –
(Sep. 24, 2025, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) hosted an international symposium titled “Accelerating Therapeutics and Vaccine for Unmet Needs” on September 29 at the institute’s main auditorium.
The symposium aimed to share strategies and the latest research trends in vaccine and therapeutic development to strengthen global preparedness against infectious diseases and to reinforce the foundation for international collaboration. The event consisted of three sessions organized by IPK and a joint session with the Peter Doherty Institute for Infection and Immunity in Australia. About 180 participants, including researchers and experts from academia, industry, and research institutes in the United States, Canada, Australia, Cambodia, and other countries, attended the event.
The symposium began with presentations on viruses, bacteria, and parasites. Professor Ian Barr from the Peter Doherty Institute for Infection and Immunity presented the current status of influenza vaccine development and discussed the potential for developing a universal influenza vaccine. Professor Eu Suk Kim from Seoul National University Bundang Hospital reviewed the current situation of antimicrobial resistance in Korea and introduced national strategies for management and response, including antimicrobial stewardship programs. Dr. Jean Popovici, Head of the Malaria Research Unit at Institut Pasteur du Cambodge, presented the characteristics of Plasmodium vivax malaria and discussed research approaches for its effective control.
The following session focused on vaccine development. Professor Amine A. Kamen from McGill University in Canada introduced recent advances in mRNA manufacturing and VSV-based vaccine platforms for rapid pandemic response. Dr. Annie De Groot, Chief Medical Officer of EpiVax in the United States, presented AI-based vaccine design and development platforms that enhance the speed and accuracy of vaccine discovery. Mr. Joo-Sung Yang, Executive Director of Samyang Group (Samyang Biopharm), introduced the company’s proprietary RNA delivery technology platform, SENS™, which enables safe and efficient delivery of RNA therapeutics and genetic vaccines.
The final part of the symposium highlighted therapeutic development. Professor Tim Stinear from the Peter Doherty Institute presented research outcomes on developing new therapeutics for methicillin-resistant Staphylococcus aureus (MRSA). Dr. David Shum, Head of the Screening Platform Laboratory at IPK, introduced an integrated drug discovery platform that combines AI and image analysis for infectious disease therapeutics. Dr. Hee-Jong Hwang, CEO of A&J Science, presented the company’s research on next-generation antibiotics derived from natural product templates.
In the joint session with the Peter Doherty Institute, the two organizations shared outcomes of their collaborative research and discussed future strategies to expand their global network. Dr. Inhee Choi, Head of the AI Drug Discovery Laboratory at IPK, and Professor Tim Stinear presented joint research on novel inhibitor candidates against methicillin-resistant Staphylococcus aureus (MRSA). Dr. Regis Grailhe, Head of the Applied Molecular Biochemistry Laboratory at IPK, introduced next-generation in vivo imaging technologies that bridge therapeutic research and technological innovation.
Through this symposium, Institut Pasteur Korea strengthened its partnerships with leading international research institutions and members of the Pasteur Network’s RAPID consortium (R&D Alliance for Preparedness of Infectious Diseases), advancing innovation in next-generation vaccines and therapeutics.
<Photo>
.png)